Catalyst Dossiers

ImmunityBio (IBRX) trades at ~$9.29 on ~1.047B shares for a ~$9.73B market cap, with reported revenue inflecting from $1M (2023) to $15M (2024) to $113M (2025) against a $351M net loss and $208M of R&D in 2025 — a profile consistent with a company in the early innings of a commercial launch while still burning heavily. Our structured coverage of this name is limited: no pipeline programs, no lead asset, and no dated catalysts are in our database, so the clinical and regulatory architecture behind that revenue ramp is not in our coverage rather than absent. The single most quantifiable tension in what we do have is balance-sheet: $205.2M cash against a burn that our model scores at roughly 8.2 months of runway, set against a valuation of ~86x trailing revenue.

PMV Pharmaceuticals is a $67M-market-cap oncology biotech with a single disclosed clinical program, rezatapopt, in Phase 2 for advanced solid tumors (mechanism not specified in our data). The company reported $12.5M in cash against a run-rate that our data flags as roughly 1.1 months of runway, alongside FY2025 R&D spend of $70M and a net loss of $78M, with an earnings update scheduled for 2026-08-20.

Cybin Inc. (HELP) is a clinical-stage psychedelic/neuropsychiatry pharma with ~50 employees and a $242M market cap trading near $11.45. Its lead asset CYB003 is in Phase 3 for Major Depressive Disorder (MDD), with a secondary program CYB004 in Phase 2 for Generalized Anxiety Disorder. A Phase 3-related catalyst is flagged in our calendar for 2026-12-31.

Scholar Rock (SRRK) is a ~$6.5B-cap biologics company whose value is concentrated in apitegromab, a Phase 3 myostatin-pathway antibody for spinal muscular atrophy (SMA). The company carries a near-term PDUFA (2026-09-30, importance 8/10) and an estimated Phase 3 readout (~2026-11-01, importance 9/10) per our calendar, against $430.5M cash and roughly 15.7 months of runway. It also holds early-stage optionality in obesity via a tirzepatide-adjacent Phase 2 program.

IN8bio, Inc. (INAB) is a clinical-stage cell therapy company focused on gamma-delta T cell platforms, with a lead autologous program in Phase 2 for glioblastoma and a second asset, INB-100, in Phase 1 for AML post-haploidentical stem cell transplant. Market cap sits at approximately $14M at ~$1.18/share. Our structured coverage of this name is materially limited — no catalysts appear in our calendar, financial figures (cash, runway, dilution) are absent from our data, and institutional/insider ownership breakdowns are not captured; all conclusions should be read as provisional given these gaps.

Iovance Biotherapeutics is a commercial-stage cell therapy company built around tumor-infiltrating lymphocyte (TIL) therapy, with lead product Amtagvi (lifileucel) already on the market for advanced melanoma and a Phase 3 confirmatory/label-expansion program combining lifileucel with pembrolizumab. FY2025 revenue reached $264M (up from $164M in 2024), but the company remains deeply unprofitable (-$391M net) and is running with only ~8 months of cash at $196.5M — the central tension in the story.

Summit Therapeutics (SMMT) is a ~160-person oncology/anti-infective developer with a ~$10.9B market cap built almost entirely on ivonescimab (AK112), a bispecific antibody licensed from Akeso, now in multiple Phase 3 NSCLC and CRC programs. The company carries a legacy C. difficile franchise (ridinilazole/SMT19969, fidaxomicin) but the valuation is a pure ivonescimab bet. A cluster of high-importance catalysts — a BLA filing and two PDUFA-tagged events — is scheduled around mid-to-late November 2026.

Acurx Pharmaceuticals (ACXP) is a micro-cap pharmaceutical company with 4 employees and a market cap of approximately $7M, trading at roughly $1.52 per share. Its sole pipeline asset is ibezapolstat, a Phase 2-stage antibiotic candidate targeting Clostridium difficile infection (CDI). No upcoming catalysts are currently calendared and key financial details including cash position, runway, and dilution history are not disclosed in available data.

Opthea Ltd (OPTEY) is a micro-cap biotechnology company with a market capitalization of approximately $7M, focused on ophthalmology. Its pipeline includes Aflibercept in Phase 2 for Diabetic Macular Edema and OPT-302 in Phase 2 for Neovascular Age-related Macular Degeneration. The dossier is severely data-constrained: financials, cash position, share count, and analyst coverage are all undisclosed in the available facts.

Genprex, Inc. (GNPX) is a small-cap clinical-stage pharmaceutical company with a market cap of approximately $85M and no revenue. Its sole disclosed pipeline asset, quaratusugene ozeplasmid, is in Phase 2 development for non-small cell lung cancer (NSCLC). The company holds $18M in cash, implying a runway of roughly 17 months.

Minerva Neurosciences (NERV) is a clinical-stage pharmaceutical company with a market cap of ~$204M and ~$32.7M in cash (runway ~18 months). Its lead asset is roluperidone 32 mg in Phase 3 for negative symptoms of schizophrenia, with a secondary Phase 2 asset (MIN-117) in major depressive disorder.

Advanced Biomed Inc. (ADVB) is a micro-cap clinical-stage company (market cap ~$12M, ~1.38M shares at ~$8.90) operating across ophthalmology, neurology, and respiratory indications with a large pipeline of SPARC-branded and partnered assets. The lead near-term catalyst is a Phase 2 readout for Vodobatinib (K0706) capsules expected August 15, 2026, followed by a PDUFA date estimated December 18, 2026. The company carries only $2.6M in cash, implying a runway of roughly 5-6 months and an acute financing overhang.

Equillium, Inc. (EQ) is a clinical-stage pharmaceutical company with a market cap of ~$156M and ~$61.3M in cash, providing roughly 43 months of runway. Its lead asset, EQ101, is in Phase 2 development for Alopecia Areata, with an August 2026 earnings call as the nearest near-term event. The mechanism of action for EQ101 is not disclosed in available data.

Odyssey Health, Inc. (ODYY) is a micro-cap medical device/instruments company with a market cap of approximately $2M, 2 employees, and a single pipeline asset — OD-07656 — in Phase 2 for Ulcerative Colitis. The company has roughly 3.3 months of cash runway ($0.6M) and no upcoming catalysts on the calendar.

Impact Biomedical Inc. (IBO) is a micro-cap pharmaceutical company with a $49M market cap, 2 employees, and a pipeline anchored by IMP4927 in Phase 3 for ovarian cancer. The company reports $0.0M cash and an estimated 0.1-month runway, making near-term financial survival the dominant question ahead of any clinical milestones.

BrainStorm Cell Therapeutics (BCLI) is a micro-cap biological products company with a market cap of approximately $8M and 23 employees, developing NurOwn® (MSC-NTF cells) as its lead asset in ALS. The company has a Phase 3 ALS program and multiple earlier-stage programs, but no disclosed near-term catalysts, no analyst coverage, and no publicly reported cash position or financial runway.

Imunon, Inc. (IMNN) is a micro-cap clinical-stage pharmaceutical company with a market cap of approximately $7M and roughly 4.2 million shares outstanding at ~$1.77. Its lead asset, IMNN-001, is an IL-12 plasmid formulated with a PEG-PEI-Cholesterol lipopolymer in Phase 3 for epithelial ovarian cancer, with a broader pipeline including ThermoDox in hepatocellular carcinoma and breast cancer, and a paclitaxel Phase 2 in ovarian cancer. The company faces acute financial distress with only $4.8M cash and an estimated 3.6-month runway.

Synlogic, Inc. (SYBX) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.66. The company is developing synthetic biotic medicines, with two Phase 2 assets — SYNB1934 and SYNB1618 — both targeting Phenylketonuria (PKU). No upcoming catalysts are currently calendared, and financial details including cash position and runway are undisclosed in available data.

Can-Fite BioPharma (CANF) is a micro-cap Israeli pharmaceutical company with a market cap of approximately $8M and only 5 employees, focused on small-molecule drug candidates targeting inflammatory and oncology indications. Its lead asset CF101 2mg is in Phase 3 for plaque psoriasis, with a second Phase 3 program in rheumatoid arthritis and Namodenoson in Phase 3 for hepatocellular carcinoma. A Phase 2 readout was reported as positive on 2026-07-15, with the next major catalyst expected by 2027-01-31.

NKGen Biotech (NKGN) is a micro-cap clinical-stage biotech with a market cap of approximately $8M and a share price near $0.07, developing SNK01 for moderate Alzheimer's disease in a Phase 2 trial. The company operates in the biological products sector with no disclosed revenue, cash position, or analyst coverage. The next meaningful data readout is estimated for December 15, 2026.

CNS Pharmaceuticals (CNSP) is a micro-cap clinical-stage biotech with 4 employees and an ~$8M market cap, focused entirely on Berubicin, an anthracycline derivative in Phase 2 for recurrent or newly diagnosed Glioblastoma Multiforme (GBM) in adults. The company holds approximately $3.0M in cash against a reported runway of under two months, creating acute near-term financing risk. No upcoming catalysts are calendared and no recent data readouts have been disclosed.

Creative Medical Technology Holdings (CELZ) is a micro-cap biotech with a $3M market cap, 4 employees, and two Phase 2 assets — CELZ-201 for Type 1 Diabetes and CELZ-201-DDT for Chronic Low-back Pain — with $5.7M cash providing roughly 13 months of runway. The company has generated no revenue across its recorded history and remains entirely dependent on external financing to advance its pipeline. The next meaningful readout is an estimated January 2027 Phase 2 data event for CELZ-201 in T1D, rated 7/10 importance.

Addex Therapeutics Ltd. (ADXN) is a micro-cap pharmaceutical company with a market cap of approximately $8M, 2 employees, and three Phase 2 assets: ADX10059 (gastroesophageal reflux), ADX48621 (Parkinson's disease), and Dipraglurant (blepharospasm). Financial details including cash, runway, and dilution history are undisclosed, though dilution risk is flagged as elevated at 27% and no upcoming catalysts are on the calendar.

Medicure Inc. (MCUJF) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.80. Its lead asset, MC-1 (Pyridoxal 5'-phosphate), is in Phase 3 development for Coronary Artery Bypass Graft Surgery (CABG) complications, with a separate Phase 3 program in Pyridox(am)ine 5'-Phosphate Oxidase Deficiency (PNPO Deficiency). A key Phase 3 readout for the PNPO Deficiency indication is estimated around November 15, 2026.

Cel-Sci Corporation (CVM) is a micro-cap clinical-stage immunotherapy company with a single disclosed pipeline asset, LEAPS Immunomodulatory (LI), currently in Phase 3 for squamous cell carcinoma of the oral cavity. At a market cap of ~$11M and reported cash of only $1.9M (~0.7 months of runway), the company faces an acute liquidity crisis that existentially overshadows any clinical optionality. No revenue has been reported in any of the last five fiscal years.

Aprea Therapeutics (APRE) is a micro-cap pharmaceutical company with a market cap of approximately $9M and 8 employees, focused on oncology. Its lead asset, APR-246 in combination with azacitidine, is in Phase 3 development for myelodysplastic syndromes (MDS), with additional pipeline programs in AML, ovarian cancer, and solid tumors. No upcoming catalysts are currently scheduled, and key financial details including cash position and runway are undisclosed.

TherapeuticsMD (TXMD) is a micro-cap pharmaceutical company with a $24M market cap, 1 reported employee, and $8.4M in cash. The company's pipeline listing is unusually broad and eclectic — spanning dozens of assets across unrelated therapeutic areas — suggesting the disclosed pipeline reflects a data aggregation artifact or licensing/tracking portfolio rather than a wholly-owned internal pipeline. Revenue has collapsed from ~$87M in 2021 to ~$3M in 2025, and the company carries a net cash position of $8.4M against ongoing operating losses.

Oxford Biomedica plc (OXB.L) is a UK-listed gene therapy company with approximately 900 employees and a reported market cap of ~$9M. Its pipeline spans oncology and neurology, led by Trovax in Phase 3 for clear cell renal carcinoma and ProSavin in Phase 2 for Parkinson's disease. Critical financial data — cash position, runway, dilution history, and revenue — are not available in the provided facts.

Innovation Pharmaceuticals Inc. (IPIX) is a micro-cap pharmaceutical company with a market capitalization of approximately $9 million and a lead asset, F14, in Phase 3 development for post-operative pain. The company maintains an unusually broad pipeline — spanning oncology, neurology, autoimmune disease, and ophthalmology — though the mechanism of action for F14 is undisclosed and financial details including cash, runway, and revenue are unavailable. Several of the pipeline assets appear to be sponsored or partnered trials rather than wholly owned IPIX programs, which materially limits the attributable value.

Kiora Pharmaceuticals (KPRX) is a micro-cap ophthalmology-focused biotech with a $11M market cap, 12 employees, and roughly $11M in cash providing approximately 10 months of runway. The company is advancing three Phase 2 assets — KIO-104 (macular edema), KIO-201 (persistent corneal epithelial defect), and KIO-301 (retinitis pigmentosa) — with the next major catalyst being Phase 2 data readout for KIO-104 estimated around November 2026.

Alaunos Therapeutics (TCRT) is a micro-cap pharmaceutical company with a $50M market cap, 1 reported employee, and approximately $0.4M in cash — implying a runway of roughly one month. The company carries a pipeline including a Phase 3 asset (doxorubicin in combination with palifosfamide-tris for soft tissue sarcoma) alongside several Phase 2 programs, but its financial position is acutely precarious.

LeonaBio, Inc. (LONA) is a clinical-stage biotech with a single disclosed asset, ATH-1017, currently in Phase 3 trials for Alzheimer's Disease. The company carries a $71M market cap against $32.8M in cash, implying a roughly $38M enterprise value, with a critical ~4.7-month cash runway that makes near-term financing essentially non-negotiable.

Fulgent Genetics (FLGT) is a medical laboratory services company with a $557M market cap, 1,313 employees, and a pipeline asset FID007 in Phase 2 for Head and Neck Squamous Cell Carcinoma. The company's revenue has collapsed from a COVID-era peak of $993M in 2021 to $323M in 2025, with persistent net losses since 2022 and only $23.4M in reported cash.

MindMed (MNMD) is a New York-based clinical-stage biotech with 57 employees and a ~$515M market cap, developing psychedelic and psychoplastogenic therapeutics. Its lead asset, MM120 (LSD D-Tartrate), is in Phase 3 for Generalized Anxiety Disorder, with earlier-stage programs in ADHD (MM120 Phase 2) and Autism Spectrum Disorder (MM402, an MDMA enantiomer, Phase 2). The company has no disclosed upcoming catalysts and carries a short interest of ~15.3% of float.

Eikon Therapeutics (EIKN) is a clinical-stage oncology company with a market cap of ~$522M and a lead asset, EIK1001, in Phase 3 for advanced melanoma. The company carries $161.2M in cash but a critically short runway of ~5.4 months, creating acute near-term financing risk alongside a pipeline spanning multiple Phase 2 oncology programs.

Altimmune, Inc. (ALT) is a clinical-stage pharmaceutical company with a market cap of ~$546M and a share price of ~$2.81. Its lead asset ALT-801 is in Phase 2 for obesity/overweight, with pemvidutide in Phase 2 for alcohol use disorder (AUD) and NasoVAX in Phase 2 for influenza. The company carries ~$97.6M in cash, representing roughly 14 months of runway, against a consistent annual cash burn of ~$85-95M.